Frontiers in Cell and Developmental Biology (Jun 2021)
Establishment and Characterization of a HER2-Positive Cell Line Derived From the Pleural Effusion of a Drug-Resistant Breast Cancer Patient
- Zhaoqing Li,
- Zhaoqing Li,
- Zhaoqing Li,
- Wenying Zhuo,
- Wenying Zhuo,
- Wenying Zhuo,
- Lini Chen,
- Lini Chen,
- Xun Zhang,
- Xun Zhang,
- Cong Chen,
- Cong Chen,
- Dengdi Hu,
- Dengdi Hu,
- Dengdi Hu,
- Yongxia Chen,
- Yongxia Chen,
- Jingjing Yang,
- Jingjing Yang,
- Yulu Zhou,
- Yulu Zhou,
- Misha Mao,
- Misha Mao,
- Ling Xu,
- Ling Xu,
- Siwei Ju,
- Siwei Ju,
- Jun Shen,
- Jun Shen,
- Qinchuan Wang,
- Qinchuan Wang,
- Minjun Dong,
- Minjun Dong,
- Shuduo Xie,
- Shuduo Xie,
- Jichun Zhou,
- Jichun Zhou,
- Linbo Wang,
- Linbo Wang
Affiliations
- Zhaoqing Li
- Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, School of Medicine, Cancer Institute, China National Ministry of Education, Zhejiang University, Hangzhou, China
- Zhaoqing Li
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Zhaoqing Li
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Wenying Zhuo
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Wenying Zhuo
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Wenying Zhuo
- The Affiliated Cixi Hospital, Wenzhou Medical University, Ningbo, China
- Lini Chen
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Lini Chen
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Xun Zhang
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Xun Zhang
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Cong Chen
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Cong Chen
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Dengdi Hu
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Dengdi Hu
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Dengdi Hu
- The Affiliated Cixi Hospital, Wenzhou Medical University, Ningbo, China
- Yongxia Chen
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Yongxia Chen
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Jingjing Yang
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Jingjing Yang
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Yulu Zhou
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Yulu Zhou
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Misha Mao
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Misha Mao
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Ling Xu
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Ling Xu
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Siwei Ju
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Siwei Ju
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Jun Shen
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Jun Shen
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Qinchuan Wang
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Qinchuan Wang
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Minjun Dong
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Minjun Dong
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Shuduo Xie
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Shuduo Xie
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Jichun Zhou
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Jichun Zhou
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- Linbo Wang
- Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Linbo Wang
- Key Laboratory of Biotherapy of Zhejiang Province, Biomedical Research Center, Hangzhou, China
- DOI
- https://doi.org/10.3389/fcell.2021.680968
- Journal volume & issue
-
Vol. 9
Abstract
Drug resistance is a daunting challenge in the treatment of breast cancer, making it an urgent problem to solve in studies. Cell lines are important tools in basic and preclinical studies; however, few breast cell lines from drug-resistant patients are available. Herein, we established a novel HER2-positive breast cancer cell line from the pleural effusion of a drug-resistant metastatic breast cancer patient. This cell line has potent proliferative capability and tumorigenicity in nude mice but weak invasive and colony-forming capability. The molecular subtype of the cell line and its sensitivity to chemotherapeutics and HER2-targeting agents are different from those of its origin, suggesting that the phenotype changes between the primary and metastatic forms of breast cancer.
Keywords
- breast cancer cell line 4Z-B-1
- HER2-positive
- invasive ductal breast carcinoma
- metastatic
- HER2 targeting
- phenotype change
